← All trials
NCT04353986
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 11, 2018
- Primary completion
- Apr 30, 2020
- Completion date
- Dec 31, 2020
- First posted
- Apr 21, 2020
- Last posted
- Apr 21, 2020
- Enrollment
- 24
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Ain Shams UniversityLead sponsor
- Ain Shams UniversityReponsible party - principal investigator
- Ain Shams UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.